Clinical pathways have become an integral part of oncology care. In use in oncology practices as early as the early 2000s, the prevalence of clinical pathways is expected to increase as the focus on value-based care...
Clinical pathways have become an integral part of oncology care. In use in oncology practices as early as the early 2000s, the prevalence of clinical pathways is expected to increase as the focus on value-based care...
For ovarian cancer, in which treatment recurrence is a challenge and long-term maintenance therapy is often required, the clinical and financial implications of long-term treatment may differ from those of other...
For ovarian cancer, in which treatment recurrence is a challenge and long-term maintenance therapy is often required, the clinical and financial implications of long-term treatment may differ from those of other...
Clinical pathways are prone to criticisms that they do not take patient diversity or the latest clinical advances into account, both of which can be addressed through comprehensive pathway design and updating...
Clinical pathways are prone to criticisms that they do not take patient diversity or the latest clinical advances into account, both of which can be addressed through comprehensive pathway design and updating...
Current clinical pathways are largely based on generalized measures such as evidence-based guidelines and consensus best practices. Yet electronic medical records (EMRs) contain a tremendous amount of data that, when...
Current clinical pathways are largely based on generalized measures such as evidence-based guidelines and consensus best practices. Yet electronic medical records (EMRs) contain a tremendous amount of data that, when...
Standardizing treatment options for relapsed/refractory multiple myeloma poses a challenge to clinical pathway decision-makers, due to the need to individualize treatment decisions for the patient’s specific...
Standardizing treatment options for relapsed/refractory multiple myeloma poses a challenge to clinical pathway decision-makers, due to the need to individualize treatment decisions for the patient’s specific...
In 2012, Dr Barbara L. McAneny was awarded a $19.76 million grant by the Center for Medicare & Medicaid Innovation to develop the Community Oncology Medical Home (COME HOME) model and implement that model in...
In 2012, Dr Barbara L. McAneny was awarded a $19.76 million grant by the Center for Medicare & Medicaid Innovation to develop the Community Oncology Medical Home (COME HOME) model and implement that model in...
Pros and Cons of Vendor- and Provider-Developed Pathways
On Day 1 of the 2018 Clinical Pathways Congress, Bobby Daly, MD, MBA, Memorial Sloan Kettering Cancer Center (New York, NY), and Robin T. Zon, MD, FACP,...
Pros and Cons of Vendor- and Provider-Developed Pathways
On Day 1 of the 2018 Clinical Pathways Congress, Bobby Daly, MD, MBA, Memorial Sloan Kettering Cancer Center (New York, NY), and Robin T. Zon, MD, FACP,...
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...